תבנית:תרופה/דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון - Docetaxel teva 20 mg/vial and 80 mg/vial: הבדלים בין גרסאות
מתוך ויקיתרופות
מ (החלפת טקסט – "|קבוצה פרמקולוגית (ATC)= {{ATC משרד הבריאות|L0" ב־"|קבוצה פרמקולוגית (ATC)={{ATC משרד הבריאות|L0") |
|||
| שורה 2: | שורה 2: | ||
|שם בעברית={{{שם בעברית|דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון}}} | |שם בעברית={{{שם בעברית|דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון}}} | ||
|שם באנגלית={{{שם באנגלית|Docetaxel teva 20 mg/vial and 80 mg/vial}}} | |שם באנגלית={{{שם באנגלית|Docetaxel teva 20 mg/vial and 80 mg/vial}}} | ||
| − | |מרכיב פעיל= | + | |מרכיב פעיל={{רווח קשיח}} |
| − | {{ | + | *[[Docetaxel]] 27.73MG / 1 ML {{כ}}[[L01CD02]] |
|קבוצה פרמקולוגית (ATC)={{ATC משרד הבריאות|L01CD|Taxanes}} | |קבוצה פרמקולוגית (ATC)={{ATC משרד הבריאות|L01CD|Taxanes}} | ||
|צורת מתן=תוך-ורידי - I.V | |צורת מתן=תוך-ורידי - I.V | ||
| שורה 10: | שורה 10: | ||
|במרשם=כן | |במרשם=כן | ||
|התוויה={{{התוויה|<div style="direction:ltr;">Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Doxorubicin and cyclophosphamide followed by Docetaxel Teva in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel Teva in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.Non-small cell lung cancerDocetaxel Teva is indicated for the treatment of patients with advanced non-small cell lung carcinoma Ovarian CancerDocetaxel Teva is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapyProstate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancerDocetaxel Teva is also indicated for the treatment of esophageal cancerGastric cancerDocetaxel Teva is also indicated for the treatment of advanced gastric cancer.Head and neck (SCCHN) • Docetaxel Teva as monotherapy is indicated in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen• Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.</div>}}} | |התוויה={{{התוויה|<div style="direction:ltr;">Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Doxorubicin and cyclophosphamide followed by Docetaxel Teva in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel Teva in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.Non-small cell lung cancerDocetaxel Teva is indicated for the treatment of patients with advanced non-small cell lung carcinoma Ovarian CancerDocetaxel Teva is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapyProstate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancerDocetaxel Teva is also indicated for the treatment of esophageal cancerGastric cancerDocetaxel Teva is also indicated for the treatment of advanced gastric cancer.Head and neck (SCCHN) • Docetaxel Teva as monotherapy is indicated in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen• Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.</div>}}} | ||
| + | |שם יצרן=[[PHARMACHEMIE B.V., THE NETHERLANDS]] | ||
| + | |שם יצרן מקוצר=[[PHARMACHEMIE]] | ||
| + | |שם בעל הרישום={{{שם בעל הרישום|[[בעל רישום::ABIC MARKETING LTD]]}}} | ||
| + | |רישיון מתאריך={{{רישיון מתאריך|[[רישום מתאריך::06/2011]]}}} | ||
| + | |תאריך הגשה=01/2011 | ||
| + | |קישור למאגר משרד הבריאות1=[ דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון] במאגר משרד הבריאות | ||
| + | |עלון לרופא={{רווח קשיח}} | ||
| + | |עלון לצרכן={{רווח קשיח}} | ||
| + | |החמרות לעלון={{רווח קשיח}} | ||
| + | |שם ללא מינון באנגלית=Docetaxel | ||
|התאמת מינון= | |התאמת מינון= | ||
|התוויות נגד= | |התוויות נגד= | ||
| שורה 18: | שורה 28: | ||
|תופעות לוואי= | |תופעות לוואי= | ||
|חיפוש בוויקירפואה= | |חיפוש בוויקירפואה= | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|מספר רישום={{{מספר רישום|146 31 33399 00}}} | |מספר רישום={{{מספר רישום|146 31 33399 00}}} | ||
|תאריך עדכון=[[עדכון אחרון::02/10/15]] | |תאריך עדכון=[[עדכון אחרון::02/10/15]] | ||
|תמונת אריזה= | |תמונת אריזה= | ||
|שיווק הופסק={{{שיווק הופסק|לא}}} | |שיווק הופסק={{{שיווק הופסק|לא}}} | ||
| − | |שם ללא מינון= | + | |שם ללא מינון=דוסיטקסל - Docetaxel |
|ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}} | |ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}} | ||
}} | }} | ||
<noinclude>{{תרופה/תיעוד}}</noinclude> | <noinclude>{{תרופה/תיעוד}}</noinclude> | ||
גרסה מתאריך 07:36, 15 במאי 2022
נתוני תרופה
במרשם 
| מינונים נוספים | |
|---|---|
| קבוצה פרמקולוגית (ATC4) | L01CD Taxanes |
| מרכיב פעיל (ATC5) | |
| צורת מתן | תוך-ורידי - I.V |
| צורת מינון | CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION |
| התוויה | Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Doxorubicin and cyclophosphamide followed by Docetaxel Teva in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel Teva in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.Non-small cell lung cancerDocetaxel Teva is indicated for the treatment of patients with advanced non-small cell lung carcinoma Ovarian CancerDocetaxel Teva is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapyProstate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancerDocetaxel Teva is also indicated for the treatment of esophageal cancerGastric cancerDocetaxel Teva is also indicated for the treatment of advanced gastric cancer.Head and neck (SCCHN) • Docetaxel Teva as monotherapy is indicated in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen• Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
|
| תבנית:נתוני סל/תרופה/דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון - Docetaxel teva 20 mg/vial and 80 mg/vial | |
| עלון לרופא והחמרות לעלון |
|
| עלון לצרכן |
|---|
| ערכים בוויקירפואה | ערכים קשורים בוויקירפואה |
|---|---|
| [ דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון] במאגר משרד הבריאות |
| חיפוש מאמרים | - |
|---|---|
| מידע ברשת | - |
| שם יצרן | PHARMACHEMIE B.V., THE NETHERLANDS |
| שם בעל הרישום | ABIC MARKETING LTD |
| רישיון | תאריך הגשה: 01/2011. רישיון מתאריך: 06/2011 |
דף זה נוצר על ידי בוט ומגדיר תבנית עם פרטי התרופה.
- דף התרופה: vial
- לדריסה ידנית של פרטי התרופה: ניתן לערוך את דף התרופה לעיל. לדוגמה החליפו את:
{{תרופה/vial}}
ב:
{{תרופה/vial
| שם הפרמטר=ערך חדש (דורס את הערך שהבוט הגדיר)
}}
